Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789552 · ClinicalTrials.gov registry record · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
A Phase 3 study of Chronic Stable Angina Pectoris, sponsored by Tasly Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 765
- Enrollment target
- 1
- Study location
NCT03789552 is a Phase 3 study of Chronic Stable Angina Pectoris that is actively recruiting participants, run by Tasly Pharmaceuticals. The registered enrollment target is 765 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03789552, a Phase 3 study of Chronic Stable Angina Pectoris, is actively recruiting participants, sponsored by Tasly Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 765 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3 clinical study to confirm the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to evaluate the long-term safety of T89. This study includes three main periods: the first study period is a 3-week single-blind qualifying run-in period to screen eligible stable angina patients by exercise tolerance test (ETT). The second study period is a 8-week double-blind treatment period to evaluate the efficacy and safety of T89 in patients with stable angina by ETT. And, the last study period is a 44-week open-label period to observe long-term use safety of T89.
Conditions Studied
Interventions
- DRUG T89 capsule
- DRUG Placebo capsule
Study Locations (1)
Florida
- Southwest Florida Research LLC - Naples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 765 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03789552
The ClinicalTrials.gov registry entry for NCT03789552 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 765 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tasly Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Stable Angina Pectoris appearing as the primary indexed condition, and to 2 interventions - of which T89 capsule is the first listed.
NCT03789552 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03789552 about?
NCT03789552 is a clinical study titled "Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina". This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3 clinical study to confirm the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to evaluate the long-term safety of T89. This study includes three main pe...
What is the current status of trial NCT03789552?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 765 participants. The study started on 2019-08-01. Estimated completion is 2027-03.
What conditions does trial NCT03789552 study?
This clinical trial studies the following conditions: Chronic Stable Angina Pectoris.
What interventions are being tested in trial NCT03789552?
The interventions under investigation include: T89 capsule (DRUG), Placebo capsule (DRUG).
Who is sponsoring clinical trial NCT03789552?
This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03789552 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.